🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Renaissance Technologies (RenTech)’s LPCN Holdings & Trades

First Buy
Q1 2015
Duration Held
35 Quarters
Largest Add
Q4 2019
+76,029 Shares
Current Position
37,397 Shares
$300,298 Value

Renaissance Technologies (RenTech)'s LPCN Position Overview

Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 37,397 shares of Lipocine Inc. (LPCN) worth $300,298, representing 0.00% of the portfolio. First purchased in 2015-Q1, this long-term strategic position has been held for 35 quarters.

Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in LPCN, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2019, adding 76,029 shares. Largest reduction occurred in Q1 2020, reducing 95,656 shares.

Analysis based on 13F filings available since 2013 Q2

Renaissance Technologies (RenTech)'s Lipocine (LPCN) Holding Value Over Time

Track share changes against reported price movement

Quarterly Lipocine (LPCN) Trades by Renaissance Technologies (RenTech)

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 +1,300 Add 3.60% 37,397 $8.03
Q3 2025 +1,300 Add 3.74% 36,097 $2.85
Q2 2025 -2,713 Reduce 7.23% 34,797 $3.16
Q1 2025 +1,478 Add 4.10% 37,510 $3.18
Q4 2024 -4,300 Reduce 10.66% 36,032 $4.88
Q3 2024 +14,635 Add 56.95% 40,332 $4.49
Q2 2024 +4,600 Add 21.80% 25,697 $8.24
Q1 2024 +2,300 Add 12.24% 21,097 $5.21
Q4 2023 +3,200 Add 20.52% 18,797 $2.77
Q3 2023 +5,200 Add 50.01% 15,597 $2.95
Q2 2023 -1,271 Reduce 10.89% 10,397 $0.01
Q1 2023 +121 Add 1.05% 11,668 $0.01
Q4 2022 -182 Reduce 1.55% 11,547 $0.01
Q3 2022 +6,964 Add 146.15% 11,729 $7.67
Q2 2022 +3,936 Add 474.79% 4,765 $13.64
Q1 2022 +829 New Buy 829 $22.92
Q3 2020 -18,594 Sold Out 0 $0.00
Q2 2020 +2,411 Add 14.90% 18,594 $21.40
Q1 2020 -95,656 Reduce 85.53% 16,183 $8.16
Q4 2019 +76,029 Add 212.31% 111,839 $6.55
Q3 2019 +6,654 Add 22.82% 35,810 $47.78
Q2 2019 +5,232 Add 21.87% 29,156 $33.17
Q1 2019 +12,065 Add 101.74% 23,924 $39.25
Q4 2018 +3,906 Add 49.11% 11,859 $22.09
Q3 2018 +1,724 Add 27.68% 7,953 $23.51
Q2 2018 +1,411 Add 29.29% 6,229 $22.15
Q1 2018 +4,818 New Buy 4,818 $25.94
Q4 2017 -13,447 Sold Out 0 $0.00
Q3 2017 +13,447 New Buy 13,447 $67.52
Q2 2016 -1,129 Sold Out 0 $0.00
Q1 2016 -9,412 Reduce 89.29% 1,129 $172.72
Q4 2015 -3,559 Reduce 25.24% 10,541 $219.81
Q3 2015 +3,285 Add 30.37% 14,100 $201.13
Q2 2015 +9,356 Add 641.26% 10,815 $145.91
Q1 2015 +1,459 New Buy 1,459 $117.20

Renaissance Technologies (RenTech)'s Lipocine Investment FAQs

Renaissance Technologies (RenTech) first purchased Lipocine Inc. (LPCN) in Q1 2015, acquiring 1,459 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Renaissance Technologies (RenTech) has held Lipocine Inc. (LPCN) for 35 quarters since Q1 2015.

Renaissance Technologies (RenTech)'s largest addition to Lipocine Inc. (LPCN) was in Q4 2019, adding 111,839 shares worth $732,000.

According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 37,397 shares of Lipocine Inc. (LPCN), valued at approximately $300,298.

As of the Q4 2025 filing, Lipocine Inc. (LPCN) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.

Renaissance Technologies (RenTech)'s peak holding in Lipocine Inc. (LPCN) was 111,839 shares, as reported at the end of Q4 2019.